Evidence map›Paper›PMID 39812703›Full record

Observational studyJournal of neurology2025

CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis.

Silvan Pless, Tim Woelfle, Johannes Lorscheider, Andrea Wiencierz, Óscar Reyes, Carlos Luque, Pasquale Calabrese, Cristina Granziera, Ludwig Kappos

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05009160 (DreaMS - Development of Digital Biomarkers in Multiple Sclerosis - Validation Study 1), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05009160 active not recruitingnot on this map

DreaMS - Development of Digital Biomarkers in Multiple Sclerosis - Validation Study 1

TypeobservationalSponsorResearch Center for Clinical Neuroimmunology and Neuroscience BaselRan2022 to 2027Enrolled300ConditionsMultiple SclerosisArmsdreaMS App R2.1
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Silvan PlessResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Spitalstrasse 2, CH-4031, Basel, Switzerland. Silvan.pless@usb.ch.ORCID http://orcid.org/0000-0002-9660-9077
Tim WoelfleResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Spitalstrasse 2, CH-4031, Basel, Switzerland.ORCID http://orcid.org/0000-0001-6279-4158
Johannes LorscheiderResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Spitalstrasse 2, CH-4031, Basel, Switzerland.ORCID http://orcid.org/0000-0003-1100-2506
Andrea WiencierzDepartment of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-8786-7915
Óscar ReyesIndivi (a DBA of Healios AG), Basel, Switzerland.ORCID http://orcid.org/0000-0003-0169-297X
Carlos LuqueIndivi (a DBA of Healios AG), Basel, Switzerland.ORCID http://orcid.org/0009-0008-2668-9826
Pasquale CalabreseNeuropsychology and Behavioral Neurology Unit, Department of Psychology and Interdisciplinary Platform Psychiatry and Psychology, Division of Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-3347-5187
Cristina GranzieraResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Spitalstrasse 2, CH-4031, Basel, Switzerland.ORCID http://orcid.org/0000-0002-4917-8761
Ludwig KapposResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Spitalstrasse 2, CH-4031, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAs part of the development of a smartphone-based app for monitoring MS disease activity and progression (dreaMS, NCT05009160), we developed six gamified tests with multiple difficulty levels as a monitoring tool for cognition. This study quantified the relative difficulty between levels and investigated their reliability, ability to depict practice effects, and user acceptance.

methodsHealthy volunteers played each game, covering five cognitive domains, twice per day for 11 consecutive days. Linear mixed models determined the relative difficulty of the levels. Spearman's correlation of the two daily repetitions measured test-retest reliability. Difficulty increased daily except for days 2, 6, and 11, when the easiest level ("Beginner") was repeated to estimate practice effects. Participants rated enjoyment and other components of acceptance on a 5-point scale.

resultsWe included 82 participants from April to July 2023 in Basel, Switzerland, of which 76 (51 female, age: 40.3 ± 13.9 years, range 18-69) completed the study according to protocol. Generally, mean performances decreased with higher difficulty levels. Across all levels of all games, the median test-retest correlation was 0.825 (range of medians 0.55-0.9). Mean performance in level "Beginner" improved across all games. The mean enjoyment rating was 3.9 (range: 3.1-4.3).

conclusionOur study showed that the CoGames yield reliable measures across different cognitive domains and difficulty levels and were enjoyable to play. The observed practice effects must be considered, but also indicate sensitivity to change. These results support the hypothesis that adaptive gamified digital tests can serve as a reliable and well-accepted monitoring tool of cognition in PwMS.

Indexed as

CognitionCognitive DysfunctionMobile ApplicationsMultiple SclerosisNeuropsychological TestsSmartphoneVideo GamesAdolescentAdultAgedFemaleHumansMaleMiddle AgedReproducibility of ResultsYoung AdultCognitive assessmentGamificationMonitoring toolMultiple sclerosisSmartphone games

Identifiers

PMID39812703
PMCPMC11735570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.